Investigational Drug Information for Seladelpar
✉ Email this page to a colleague
What is the drug development status for Seladelpar?
Seladelpar is an investigational drug.
There have been 11 clinical trials for Seladelpar.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2018.
The most common disease conditions in clinical trials are Cholangitis, Liver Cirrhosis, Biliary, and Liver Diseases. The leading clinical trial sponsors are CymaBay Therapeutics, Inc. and [disabled in preview].
There are twenty-one US patents protecting this investigational drug and three hundred and one international patents.
Summary for Seladelpar
| US Patents | 21 |
| International Patents | 301 |
| US Patent Applications | 128 |
| WIPO Patent Applications | 54 |
| Japanese Patent Applications | 10 |
| Clinical Trial Progress | Phase 3 (2018-10-01) |
| Vendors | 37 |
Recent Clinical Trials for Seladelpar
| Title | Sponsor | Phase |
|---|---|---|
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | CymaBay Therapeutics, Inc. | Phase 3 |
| IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | CymaBay Therapeutics, Inc. | Phase 3 |
| An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) | CymaBay Therapeutics, Inc. | Phase 1 |
Clinical Trial Summary for Seladelpar
Top disease conditions for Seladelpar
Top clinical trial sponsors for Seladelpar
US Patents for Seladelpar
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Seladelpar | ⤷ Sign Up | Combination therapy | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | ⤷ Sign Up |
| Seladelpar | ⤷ Sign Up | Medical use of pharmaceutical combination or composition | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | ⤷ Sign Up |
| Seladelpar | ⤷ Sign Up | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome | Boehringr Ingelheim International GmbH (Ingelheim am Rhein, DE) | ⤷ Sign Up |
| Seladelpar | ⤷ Sign Up | Treatment of intrahepatic cholestatic diseases | CymaBay Therapeutics, Inc. | ⤷ Sign Up |
| Seladelpar | ⤷ Sign Up | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | Janssen Pharmaceutical N.V. (Beerse, BE) | ⤷ Sign Up |
| Seladelpar | ⤷ Sign Up | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | Janssen Pharmaceutica NV (Beerse, BE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Seladelpar
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Seladelpar | Australia | AU2011249722 | 2030-05-05 | ⤷ Sign Up |
| Seladelpar | Brazil | BR112012028136 | 2030-05-05 | ⤷ Sign Up |
| Seladelpar | Canada | CA2797310 | 2030-05-05 | ⤷ Sign Up |
| Seladelpar | Canada | CA3070513 | 2030-05-05 | ⤷ Sign Up |
| Seladelpar | Chile | CL2012003053 | 2030-05-05 | ⤷ Sign Up |
| Seladelpar | China | CN102946875 | 2030-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
